KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2019)

Arbutus Biopharma (ABUS) has disclosed Cash from Restructuring for 2 consecutive years, with -$66000.0 as the latest value for Q4 2019.

  • Quarterly Cash from Restructuring fell 107.06% to -$66000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was -$845000.0 through Dec 2019, down 141.73% year-over-year, with the annual reading at -$983000.0 for FY2019, 173.85% down from the prior year.
  • Cash from Restructuring hit -$66000.0 in Q4 2019 for Arbutus Biopharma, up from -$640000.0 in the prior quarter.
  • In the past five years, Cash from Restructuring ranged from a high of $1.0 million in Q1 2018 to a low of -$640000.0 in Q2 2019.